Last reviewed 2026-05-22 · How we verify

Rabbit ATG, (Genzyme)

Rabbit ATG, (Genzyme) is a Polyclonal antithymocyte globulin (ATG) Small molecule drug developed by Jinan Military General Hospital. It is currently FDA-approved for Prevention of acute organ rejection in renal transplantation, Treatment of acute rejection episodes in transplant recipients, Aplastic anemia. Also known as: Thymoglobuline, Anti-thymoeyteGlobulin.

Rabbit ATG is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering complement-mediated and antibody-dependent cellular cytotoxicity.

Rabbit ATG, also known as Thymoglobulin, is a biological vaccine that induces an immune response. It has been studied in clinical trials for various conditions, including Sickle Cell Disease, Graft Versus Host Disease, Aplastic Anemia, Nijmegen Breakage Syndrome, and Crohn's Disease.

At a glance

Mechanism of action

Rabbit ATG is derived from immunized rabbits and contains polyclonal antibodies against human T-cell antigens. It binds to circulating and tissue-resident T cells, leading to their elimination through complement activation and antibody-dependent cell-mediated cytotoxicity. This profound immunosuppression is used to prevent graft rejection and treat T-cell mediated conditions.

Approved indications

• Prevention of acute organ rejection in renal transplantation
• Treatment of acute rejection episodes in transplant recipients
• Aplastic anemia

Common side effects

• Fever
• Chills
• Thrombocytopenia
• Leukopenia
• Serum sickness
• Infection
• Rash

Key clinical trials

• Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
• The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
• 1 vs 7 RATG Infusions in Renal Transplantation
• ATG Plus Low-dose PT-Cy for GVHD Prevention (PHASE3)
• Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease (PHASE1)
• Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome (PHASE2)
• Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia (PHASE2)
• The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Rabbit ATG, (Genzyme) CI brief — competitive landscape report
• Rabbit ATG, (Genzyme) updates RSS · CI watch RSS
• Jinan Military General Hospital portfolio CI

Frequently asked questions about Rabbit ATG, (Genzyme)

Related

• Drug class: All Polyclonal antithymocyte globulin (ATG) drugs
• Target: All drugs targeting T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
• Manufacturer: Jinan Military General Hospital — full pipeline
• Therapeutic area: All drugs in Immunology
• Indication: Drugs for Prevention of acute organ rejection in renal transplantation
• Indication: Drugs for Treatment of acute rejection episodes in transplant recipients
• Indication: Drugs for Aplastic anemia
• Also known as: Thymoglobuline, Anti-thymoeyteGlobulin

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing